Be
BerGenBio
Bergen NOFounded 200750 employees
Private CapbiotechAcquiredOncology
Platform: Bemcentinib AXL
Market Cap
N/A
All Drugs
4
Clinical Trials
12
Failed / Terminated
3
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| BER-6819 | BER-6819 | Phase 2/3 | 1 | PRMT5 | Gastric CaHeart Failure | ||
| BER-6094 | BER-6094 | Phase 3 | 4 | CDK2 | OCDNB | ||
| BER-3725 | BER-3725 | Phase 3 | 4 | FXIa | WMAS | ||
| Pexainavolisib | BER-6978 | Approved | 3 | BCMA | SMAFTD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (10)